iTeos Therapeutics SA Revenue and Competitors
Estimated Revenue & Valuation
- iTeos Therapeutics SA's estimated annual revenue is currently $36.8M per year.
- iTeos Therapeutics SA's estimated revenue per employee is $193,750
- iTeos Therapeutics SA's total funding is $249.7M.
Employee Data
- iTeos Therapeutics SA has 190 Employees.
- iTeos Therapeutics SA grew their employee count by 42% last year.
iTeos Therapeutics SA's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-founder, President & CEO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Chief Accountant | Reveal Email/Phone |
4 | VP, Head Pharmacovigilance | Reveal Email/Phone |
5 | VP, Medical Affairs | Reveal Email/Phone |
6 | VP Clinical Development | Reveal Email/Phone |
7 | Head Investor Relations | Reveal Email/Phone |
8 | Head MW | Reveal Email/Phone |
9 | Head ClinOps Center Excellence | Reveal Email/Phone |
10 | VP Project Head | Reveal Email/Phone |
iTeos Therapeutics SA Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is iTeos Therapeutics SA?
Starting operations in 2012, iTeos Therapeutics is a clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by developing immunotherapies by design. iTeos is developing EOS200271, a clinical-stage potent and selective IDO1 inhibitor with exceptional brain penetration. The company is also advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase 1 trial in the second half of 2018; and a human ADCC-enabling anti-TIGIT antibody (EOS884448), representing an additional, third clinical entry in 2019. Based in Gosselies, Belgium, iTeos Therapeutics was founded and supported in part by investments from the Ludwig Institute Cancer Research (LICR), the Walloon Region of Belgium and the European Fund for Economic and Regional Development (FEDER). For more information, please visit www.iteostherapeutics.com.
keywords:N/A
$249.7M
Total Funding
190
Number of Employees
$36.8M
Revenue (est)
42%
Employee Growth %
N/A
Valuation
N/A
Accelerator
iTeos Therapeutics SA News
Venture capitalists are investing $125 million to fuel a push by iTeos Therapeutics Inc. to cure more cancer patients through immunotherapy. New cancer immunotherapies boost immune cells’ ability to fight tumors. Over the past decade, Merck & Co. and other companies have introduced drugs design ...
iTeos Therapeutics Inc., a Cambridge, MA and Gosselies, Belgium – based clinical-stage biotechnology company developing innovative cancer immunotherapies, closed a $125m Series B2 financing. The round was co-led by RA Capital Management and Boxer Capital, with participation from new investors J ...
Venture capitalists are investing $125 million to fuel a push by iTeos Therapeutics Inc. to cure more cancer patients through immunotherapy. New cancer immunotherapies boost immune cells’ ability to fight tumors. Over the past decade, Merck & Co. and other companies have introduced drugs design ...